Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 8/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 8/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.66 |
| ▸ | PDE4A | P27815 | 2/20 | 0.66 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.66 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.66 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.66 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | THPO | P40225 | 1/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.65 |
| ▸ | LMNA | P02545 | 4/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31619806 | 1.00 | TSHR (0.66) | TSHRMAPK1MAPTCYP3A4TDP1 | |
| SCHEMBL5113231 | 1.00 | TSHR (0.66) | TSHRMAPK1MAPTCYP3A4TDP1 | |
| SCHEMBL5113232 | 1.00 | TSHR (0.66) | TSHRMAPK1MAPTCYP3A4TDP1 | |
| SCHEMBL31620968 | 0.94 | TSHR (0.59) | TSHRMAPK1MAPTCYP3A4TDP1 | |
| SCHEMBL31632614 | 0.94 | TSHR (0.59) | TSHRMAPK1MAPTCYP3A4TDP1 | |
| SCHEMBL21621325 | 0.93 | TSHR (0.59) | TSHRMAPK1MAPTCYP3A4TDP1 | |
| SCHEMBL31620983 | 0.93 | TSHR (0.57) | TSHRMAPK1MAPTCYP3A4TDP1 | |
| SCHEMBL31620981 | 0.92 | TSHR (0.56) | TSHRMAPK1MAPTCYP3A4TDP1 | |
| SCHEMBL25773363 | 0.92 | TSHR (0.56) | TSHRMAPK1MAPTCYP3A4TDP1 | |
| SCHEMBL25773255 | 0.90 | TSHR (0.54) | TSHRMAPK1MAPTCYP3A4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024127413-A1 | SOLID STATE FORMS OF ENSIFENTRINE | CIPLA LIMITED (IN) | 2024-06-20 | — | — | WO | claimed |
| EP-4731183-A1 | PARTICULATE COMPOSITION COMPRISING ENSIFETRINE | Verona Pharma PLC (GB) | 2026-04-29 | — | — | EP | disclosed |
| WO-2026003867-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF ENSIFENTRINE AND ITS PURIFICATION THEREOF | NEULAND LABORATORIES LIMITED (IN) | 2026-01-02 | — | — | WO | disclosed |
| US-20250249008-A1 | PHARMACEUTICAL COMPOSITIONS OF ENSIFENTRINE FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | VERONA PHARMA PLC (GB) | 2025-08-07 | — | — | US | disclosed |
| US-20250249007-A1 | PHARMACEUTICAL COMPOSITIONS OF ENSIFENTRINE FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | VERONA PHARMA PLC (GB) | 2025-08-07 | — | — | US | disclosed |
| US-20250170135-A1 | PARTICULATE COMPOSITION | VERONA PHARMA PLC (GB) | 2025-05-29 | — | — | US | disclosed |
| US-12251384-B1 | Particulate composition | VERONA PHARMA PLC (GB) | 2025-03-18 | — | — | US | disclosed |
| WO-2025052119-A1 | ENSIFENTRINE FOR USE IN TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) | VERONA PHARMA PLC (GB) | 2025-03-13 | — | — | WO | disclosed |
| US-20250073240-A1 | NEW TREATMENT | VERONA PHARMA LIMITED (GB) | 2025-03-06 | — | — | US | disclosed |
| US-20250064815-A1 | PARTICULATE COMPOSITION | VERONA PHARMA PLC (GB) | 2025-02-27 | — | — | US | disclosed |
| US-10710998-B2 | Compound and process | VERONA PHARMA PLC (GB) | 2020-07-14 | — | — | US | disclosed |
| US-20190330206-A1 | NEW COMPOUND AND PROCESS | VERONA PHARMA LIMITED (GB) | 2019-10-31 | — | — | US | disclosed |
| EP-3490988-B1 | NEW COMPOUND AND PROCESS | VERONA PHARMA PLC (GB) | 2019-08-28 | — | — | EP | disclosed |
| WO-2018020249-A1 | NEW COMPOUND AND PROCESS | VERONA PHARMA PLC (GB) | 2018-02-01 | — | — | WO | disclosed |
| US-8242127-B2 | INHIBITORS OF PHOSPHODIESTERASE (PDE) ISOENZYMES; USEFUL FOR TREATMENT OF RESPIRATORY DISORDERS SUCH AS ASTHMA; chronic obstructive pulmonary disease (COPD); 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one | VERONA PHARMA PLC (GB) | 2012-08-14 | — | — | US | disclosed |
| US-8242127-B2 | INHIBITORS OF PHOSPHODIESTERASE (PDE) ISOENZYMES; USEFUL FOR TREATMENT OF RESPIRATORY DISORDERS SUCH AS ASTHMA; chronic obstructive pulmonary disease (COPD); 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one | VERONA PHARMA PLC (GB) | 2012-08-14 | — | — | US | disclosed |
| US-20080206163-A1 | Derivatives of pyrimido[6, 1-A]isoquinolin-4-one | VERONA PHARMA PLC (GB) | 2008-08-28 | — | — | US | disclosed |
| US-20080206163-A1 | Derivatives of pyrimido[6, 1-A]isoquinolin-4-one | VERONA PHARMA PLC (GB) | 2008-08-28 | — | — | US | disclosed |
| US-7378424-B2 | Derivatives of pyrimido[6, 1-A]isoquinolin-4-one | VERONA PHARMA PLC (GB) | 2008-05-27 | — | — | US | disclosed |
| US-7378424-B2 | Derivatives of pyrimido[6, 1-A]isoquinolin-4-one | VERONA PHARMA PLC (GB) | 2008-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250073240-A1 | NEW TREATMENT | ELANE, EPX, EDNRA | TSHR 1649/4885MAPK1 1819/4885MAPT 2879/4885 |
| US-12251384-B1 | Particulate composition | INMT, PNMT, HTR7 | TSHR 2461/4885MAPK1 3137/4885MAPT 342/4885 |
| US-20190330206-A1 | NEW COMPOUND AND PROCESS | RPL4, EIF5B, RPLP2 | TSHR 4279/4885MAPK1 2255/4885MAPT 3273/4885 |
| US-20250170135-A1 | PARTICULATE COMPOSITION | INMT, PNMT, HTR7 | TSHR 2449/4885MAPK1 3099/4885MAPT 322/4885 |
| US-20250249008-A1 | PHARMACEUTICAL COMPOSITIONS OF ENSIFENTRINE FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | EPX, ELANE, EDNRA | TSHR 1098/4885MAPK1 4245/4885MAPT 3077/4885 |
| US-20250249007-A1 | PHARMACEUTICAL COMPOSITIONS OF ENSIFENTRINE FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | EDNRA, EDNRB, OGFR | TSHR 1717/4885MAPK1 4043/4885MAPT 1402/4885 |
| US-10710998-B2 | Compound and process | RPL4, EIF5B, RPLP1 | TSHR 4409/4885MAPK1 2487/4885MAPT 3018/4885 |
| US-20250064815-A1 | PARTICULATE COMPOSITION | INMT, PNMT, HTR7 | TSHR 2461/4885MAPK1 3137/4885MAPT 342/4885 |
| US-20080206163-A1 | Derivatives of pyrimido[6, 1-A]isoquinolin-4-one | HRH2, HRH4, TAS2R3 | TSHR 368/4885MAPK1 1893/4885MAPT 4699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.